RecruitingNCT07063043

Clinical Research on 68Ga-FAPI PET/CMR in Cardiovascular Diseases


Sponsor

Shanghai East Hospital

Enrollment

40 participants

Start Date

Dec 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

FAP-targeted PET imaging using 68Ga-FAPI enables early detection of myocardial fibrosis. Combined PET/CMR provides comprehensive cardiac assessment without extra radiation. This advanced imaging approach improves diagnosis and personalized treatment for better patient outcomes.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Participants must have a confirmed clinical diagnosis of cardiovascular disease by a cardiologist, based on genetic testing, family history, and comprehensive clinical evaluation including physical examination, echocardiography, and when indicated, cardiac MRI findings.
  • Age requirement: >18 years.
  • Patients should demonstrate stable cardiovascular status without significant changes in symptoms, treatment, or clinical findings for a specified pre-enrollment period.
  • Participants must be capable of providing informed consent and willing to adhere to all study requirements, including follow-up procedures.

Exclusion Criteria7

  • History of malignancy
  • Documented cardiovascular diseases, including coronary artery disease, myocardial infarction, or related conditions
  • Implanted metallic devices (e.g., pacemakers, aneurysm clips) or other MRI-incompatible medical prostheses
  • Claustrophobia
  • Pregnancy or lactation
  • Known hypersensitivity to gadolinium-based contrast agents
  • Renal impairment (eGFR <30 mL/min/1.73m² by CKD-EPI equation)

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Shanghai East Hospital

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07063043


Related Trials